Chiglitazar Enhances Imatinib Sensitivity in Chronic Myeloid Leukemia
Author Information
Author(s): Duan Hongpeng, Lai Qian, Jiang Yuelong, Yang Liuzhen, Deng Manman, Lin Zhijuan, Shan Weihang, Zhong Mengya, Yao Jingwei, Zhang Li, Xu Bing, Zha Jie
Primary Institution: The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University
Hypothesis
Combining Chiglitazar with Imatinib may overcome Imatinib resistance in Chronic Myeloid Leukemia (CML) by modulating glucose metabolism.
Conclusion
Chiglitazar can help overcome Imatinib resistance in CML by inhibiting the Warburg effect and enhancing sensitivity to treatment.
Supporting Evidence
- Chiglitazar reduced glucose and lactate production in imatinib-resistant CML cells.
- The combination of Chiglitazar and Imatinib significantly increased apoptosis in resistant cells.
- Chiglitazar modulated the Warburg effect through the PPARγ/mTOR/PKM2 pathway.
- In vivo studies showed prolonged survival of mice treated with both Chiglitazar and Imatinib.
Takeaway
Chiglitazar is a medicine that helps make another cancer drug, Imatinib, work better for patients with a type of blood cancer called CML.
Methodology
CML cells were treated with Chiglitazar and Imatinib in vitro and in vivo, with assessments of cell proliferation, apoptosis, and metabolic changes.
Limitations
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website